Healthcare [ 5/11 ] | Biotechnology [ 72/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 23 | 0.06 Increased by +200.00% | 0.06 |
| May 15, 23 | -0.05 Increased by 0.00% | -0.06 Increased by +16.67% |
| Mar 23, 23 | -0.06 Decreased by -50.00% | -0.06 |
| Mar 22, 23 | -0.06 Decreased by -50.00% | -0.06 |
| Nov 7, 22 | -0.06 Decreased by -50.00% | -0.06 |
| Aug 8, 22 | -0.05 Increased by +16.67% | -0.06 Increased by +16.67% |
| May 9, 22 | -0.04 Increased by 0.00% | -0.05 Increased by +20.00% |
| Feb 28, 22 | -0.04 Increased by +95.45% | -0.04 Decreased by -11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.83 M Decreased by -45.65% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.46 M Decreased by -13.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -6.84 M Decreased by -41.55% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -7.82 M Decreased by -49.30% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -6.75 M Increased by +4.60% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -4.83 M Decreased by -36.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -4.84 M Increased by +35.39% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -5.24 M Decreased by -50.74% | Decreased by N/A% Decreased by N/A% |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.